Regulatory considerations in biosimilars: Asia pacific regions

Biosimilars are the biological drugs that are granted after the expiry of the patent of an affirmed innovator. Asia Pacific countries are characterized by significant demand as they account for majority of the world population and poor affordability due to low per capita income in most regions. Some...

Full description

Saved in:
Bibliographic Details
Published in:Preparative biochemistry & biotechnology 2021, Vol.51 (1), p.1-8
Main Authors: Rathore, Anurag S., Bhargava, Ankita
Format: Article
Language:English
Subjects:
Approved status
Asia Pacific - biosimilars
Biological products
key players
market size
regulatory framework
World population
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biosimilars are the biological drugs that are granted after the expiry of the patent of an affirmed innovator. Asia Pacific countries are characterized by significant demand as they account for majority of the world population and poor affordability due to low per capita income in most regions. Some of these countries offer potential to emerge as global suppliers of affordable, safe and efficacious biosimilars. This article highlights the prospects of biosimilars in the Asia Pacific market. Regulatory framework in the various countries is also discussed.
ISSN:1082-6068
1532-2297
DOI:10.1080/10826068.2020.1815061